Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system
ConclusionDespite the significant gains of abemaciclib as adjuvant treatment in terms of progression-free survival, this treatment is not cost-effective for the Spanish National Health System at published prices. It may be cost-effective with an appropriate discount on the official price.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Economics | Health Management | HER2 | Hormonal Therapy | Hormones | Oral Cancer | Spain Health | Women